Adjuvant therapy in high-risk prostate cancer

Jeffrey Shevach, Parul Chaudhuri, Alicia Katherine Morgans*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prostate cancer, the role of systemic adjuvant therapy has remained relatively stagnant over the last few decades for patients with high-risk disease, consisting of only androgen deprivation therapy. Novel methods of risk stratification, however, based on traditional clinicopathologic features combined with genomic data, will allow investigators to study adjuvant therapy with more precision in high-risk populations. Additionally, the rise of novel hormonal therapies may provide oncologists with more efficacious drugs in the adjuvant setting, potentially leading to effective adjuvant therapy options for clinicians treating men with high-risk localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume17
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Therapeutics
Treatment Failure
Androgens
Research Personnel
Morbidity
Mortality
Pharmaceutical Preparations
Population
Neoplasms

Keywords

  • Adjuvant therapy
  • CAPRA-S
  • Decipher
  • High-risk prostate cancer
  • Localized prostate cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Shevach, Jeffrey ; Chaudhuri, Parul ; Morgans, Alicia Katherine. / Adjuvant therapy in high-risk prostate cancer. In: Clinical Advances in Hematology and Oncology. 2019 ; Vol. 17, No. 1. pp. 45-53.
@article{0310d3170eae44a28ac26be1953bd6d4,
title = "Adjuvant therapy in high-risk prostate cancer",
abstract = "Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prostate cancer, the role of systemic adjuvant therapy has remained relatively stagnant over the last few decades for patients with high-risk disease, consisting of only androgen deprivation therapy. Novel methods of risk stratification, however, based on traditional clinicopathologic features combined with genomic data, will allow investigators to study adjuvant therapy with more precision in high-risk populations. Additionally, the rise of novel hormonal therapies may provide oncologists with more efficacious drugs in the adjuvant setting, potentially leading to effective adjuvant therapy options for clinicians treating men with high-risk localized prostate cancer.",
keywords = "Adjuvant therapy, CAPRA-S, Decipher, High-risk prostate cancer, Localized prostate cancer",
author = "Jeffrey Shevach and Parul Chaudhuri and Morgans, {Alicia Katherine}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "17",
pages = "45--53",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "1",

}

Adjuvant therapy in high-risk prostate cancer. / Shevach, Jeffrey; Chaudhuri, Parul; Morgans, Alicia Katherine.

In: Clinical Advances in Hematology and Oncology, Vol. 17, No. 1, 01.01.2019, p. 45-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant therapy in high-risk prostate cancer

AU - Shevach, Jeffrey

AU - Chaudhuri, Parul

AU - Morgans, Alicia Katherine

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prostate cancer, the role of systemic adjuvant therapy has remained relatively stagnant over the last few decades for patients with high-risk disease, consisting of only androgen deprivation therapy. Novel methods of risk stratification, however, based on traditional clinicopathologic features combined with genomic data, will allow investigators to study adjuvant therapy with more precision in high-risk populations. Additionally, the rise of novel hormonal therapies may provide oncologists with more efficacious drugs in the adjuvant setting, potentially leading to effective adjuvant therapy options for clinicians treating men with high-risk localized prostate cancer.

AB - Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prostate cancer, the role of systemic adjuvant therapy has remained relatively stagnant over the last few decades for patients with high-risk disease, consisting of only androgen deprivation therapy. Novel methods of risk stratification, however, based on traditional clinicopathologic features combined with genomic data, will allow investigators to study adjuvant therapy with more precision in high-risk populations. Additionally, the rise of novel hormonal therapies may provide oncologists with more efficacious drugs in the adjuvant setting, potentially leading to effective adjuvant therapy options for clinicians treating men with high-risk localized prostate cancer.

KW - Adjuvant therapy

KW - CAPRA-S

KW - Decipher

KW - High-risk prostate cancer

KW - Localized prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85061860236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061860236&partnerID=8YFLogxK

M3 - Article

C2 - 30843898

AN - SCOPUS:85061860236

VL - 17

SP - 45

EP - 53

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 1

ER -